title: The prevalence of acromegaly in hospitalized patients with type 2 diabetes.
abstract: The prevalence of acromegaly is estimated to be 8-24/100,000, but several recent studies suggest it is underestimated. In particular, acromegaly is considered more prevalent in patients with type 2 diabetes mellitus (T2DM) than in the normal population. This study aimed to evaluate the prevalence of acromegaly in hospitalized patients with T2DM. A total of 327 hospitalized patients with T2DM were recruited as subjects. If serum insulin-like growth factor 1 (IGF-1) levels were found to be elevated, random GH level was measured or oral glucose tolerance test (OGTT) was performed. Five patients with elevated serum IGF-1 levels and random GH level or inadequate suppression of GH in the OGTT underwent pituitary magnetic resonance imaging. Of those patients, pituitary adenoma was detected in 2 patients. These 2 patients were diagnosed with acromegaly, as they also exhibited mild acromegalic features. Intriguingly, both these patients exhibited severe macroangiopathy and an absence of microangiopathy. The prevalence of acromegaly in the hospitalized patients with T2DM in this study was therefore 0.6%, suggesting a higher prevalence than that predicted. Although a large-scale prospective study is required to clarify the precise prevalence of acromegaly in hospitalized patients with T2DM, the present study shows that it is useful to screen hospitalized patients with T2DM for acromegaly by measuring their serum IGF-1 level.
authors.affiliation: Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Japan.
authors.forename: Kentaro
authors.initials: K
authors.lastname: Suda
authors.forename: Hidenori
authors.initials: H
authors.lastname: Fukuoka
authors.forename: Genzo
authors.initials: G
authors.lastname: Iguchi
authors.forename: Yushi
authors.initials: Y
authors.lastname: Hirota
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Nishizawa
authors.forename: Hironori
authors.initials: H
authors.lastname: Bando
authors.forename: Ryusaku
authors.initials: R
authors.lastname: Matsumoto
authors.forename: Michiko
authors.initials: M
authors.lastname: Takahashi
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Sakaguchi
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Takahashi
mesh_terms: D000172:Acromegaly / Q000209:etiology*; D000236:Adenoma / Q000150:complications* / Q000453:epidemiology / Q000378:metabolism / Q000503:physiopathology; D000328:Adult; D000368:Aged; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications* / Q000628:therapy; D005260:Female; D049912:Growth Hormone-Secreting Pituitary Adenoma / Q000150:complications* / Q000453:epidemiology / Q000378:metabolism / Q000503:physiopathology; D006760:Hospitalization; D006785:Hospitals, University; D019382:Human Growth Hormone / Q000097:blood / Q000378:metabolism; D006801:Humans; D018970:Insulin-Like Growth Factor Binding Protein 1 / Q000097:blood; D007564:Japan / Q000453:epidemiology; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D010902:Pituitary Gland / Q000378:metabolism; D015995:Prevalence; D012189:Retrospective Studies; D015854:Up-Regulation
chemical_list: C032231:IGFBP1 protein, human; D018970:Insulin-Like Growth Factor Binding Protein 1; D019382:Human Growth Hormone